Mustang Bio (MBIO) Cash & Equivalents (2016 - 2026)

Mustang Bio (MBIO) has reported Cash & Equivalents for 11 consecutive years, with $16.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 14.24% year-over-year to $16.3 million; the TTM figure through Mar 2026 stood at $16.3 million (up 14.24% YoY), while the FY2025 annual figure was $17.3 million, up 152.46% from the prior year.
• Cash & Equivalents slipped to $16.3 million in Q1 2026 per MBIO's latest filing, from $17.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $122.2 million in Q1 2022 and bottomed at $1.3 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $34.2 million across 5 years, with a median of $15.4 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 7465.6% — and 2024, when it tumbled 97.7%.
• Mustang Bio's Cash & Equivalents stood at $75.7 million in 2022, then tumbled by 91.76% to $6.2 million in 2023, then gained by 9.7% to $6.8 million in 2024, then jumped by 152.46% to $17.3 million in 2025, then declined by 5.84% to $16.3 million in 2026.
• Business Quant data shows MBIO's Cash & Equivalents at $16.3 million in Q1 2026, $17.3 million in Q4 2025, and $19.0 million in Q3 2025.